364 related articles for article (PubMed ID: 30049957)
1. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
[TBL] [Abstract][Full Text] [Related]
2. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
3. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.
Barghout SH; Zepeda N; Xu Z; Steed H; Lee CH; Fu Y
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):173-8. PubMed ID: 26522223
[TBL] [Abstract][Full Text] [Related]
4. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer.
Pan JX; Qu F; Wang FF; Xu J; Mu LS; Ye LY; Li JJ
Arch Gynecol Obstet; 2017 Dec; 296(6):1145-1152. PubMed ID: 28975405
[TBL] [Abstract][Full Text] [Related]
5. Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer.
Xie Y; Peng Z; Shi M; Ji M; Guo H; Shi H
Mol Med Rep; 2014 Nov; 10(5):2346-50. PubMed ID: 25118792
[TBL] [Abstract][Full Text] [Related]
6. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.
Wen J; Cheng HY; Feng Y; Rice L; Liu S; Mo A; Huang J; Zu Y; Ballon DJ; Chang CC
Br J Haematol; 2008 Jan; 140(2):169-80. PubMed ID: 18173754
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
8. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
9. Exosomes as mediators of platinum resistance in ovarian cancer.
Crow J; Atay S; Banskota S; Artale B; Schmitt S; Godwin AK
Oncotarget; 2017 Feb; 8(7):11917-11936. PubMed ID: 28060758
[TBL] [Abstract][Full Text] [Related]
10. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Zhang YX; Kong CZ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
[TBL] [Abstract][Full Text] [Related]
11. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells.
Ali JL; Lagasse BJ; Minuk AJ; Love AJ; Moraya AI; Lam L; Arthur G; Gibson SB; Morrison LC; Werbowetski-Ogilvie TE; Fu Y; Nachtigal MW
Int J Cancer; 2015 Mar; 136(5):E455-69. PubMed ID: 25227893
[TBL] [Abstract][Full Text] [Related]
12. [Effects and mechanisms of platelet-activating factor on the invasiveness of ovarian cancer cells in vitro].
Jiang W; Wang YS; Cong Q; Li MJ; Ye B; Xu CJ
Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):931-5. PubMed ID: 22333285
[TBL] [Abstract][Full Text] [Related]
13. Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells.
Pastò A; Pagotto A; Pilotto G; De Paoli A; De Salvo GL; Baldoni A; Nicoletto MO; Ricci F; Damia G; Bellio C; Indraccolo S; Amadori A
Oncotarget; 2017 Jan; 8(4):6433-6445. PubMed ID: 28031535
[TBL] [Abstract][Full Text] [Related]
14. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z
Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244
[TBL] [Abstract][Full Text] [Related]
15. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
[TBL] [Abstract][Full Text] [Related]
16. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
17. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance.
Barancík M; Bohácová V; Kvackajová J; Hudecová S; Krizanová O; Breier A
Eur J Pharm Sci; 2001 Aug; 14(1):29-36. PubMed ID: 11457647
[TBL] [Abstract][Full Text] [Related]
18. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
[TBL] [Abstract][Full Text] [Related]
19. Induction of autophagy in hepatocellular carcinoma cells by SB203580 requires activation of AMPK and DAPK but not p38 MAPK.
Zhang H; Chen GG; Zhang Z; Chun S; Leung BC; Lai PB
Apoptosis; 2012 Apr; 17(4):325-34. PubMed ID: 22170404
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]